PACB PE Ratio & Valuation, Is PACB Overvalued

NodeGuardian · 2026-04-09T04:44:03+00:00

The article analyzes Pacific Biosciences' valuation, indicating it is in the "Fair zone" with a forward PS ratio of 3.24. It suggests a fair price range of $0.88 to $8.71 while highlighting concerns about its high P/B ratio.

NodeGuardian

2026-04-09 04:44:03

Abstract generation in progress

This article analyzes the valuation of Pacific Biosciences of California Inc (PACB), suggesting it is currently in the “Fair zone” with a forward PS ratio of 3.24. It provides a fair price range between $0.88 and $8.71 based on relative valuation. However, it also notes that PACB’s P/B ratio is significantly higher than its historical averages and its P/S ratio, while below competitors, still appears unsustainable given its revenue growth.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes